Prognostic impact of tumor‑infiltrating CD276/Foxp3‑positive lymphocytes and associated circulating cytokines in patients undergoing radical nephrectomy for localized renal cell carcinoma

Iida,Kota; Miyake,Makito; Onishi,Kenta; Hori,Shunta; Morizawa,Yosuke; Gotoh,Daisuke; Itami,Yoshitaka; Onishi,Sayuri; Nakai,Yasushi; Anai,Satoshi; Tanaka,Nobumichi; Fujimoto,Kiyohide

doi:10.3892/ol.2019.10057

Prognostic impact of tumor‑infiltrating CD276/Foxp3‑positive lymphocytes and associated circulating cytokines in patients undergoing radical nephrectomy for localized renal cell carcinoma

Authors:
- Kota Iida
- Makito Miyake
- Kenta Onishi
- Shunta Hori
- Yosuke Morizawa
- Daisuke Gotoh
- Yoshitaka Itami
- Sayuri Onishi
- Yasushi Nakai
- Satoshi Anai
- Nobumichi Tanaka
- Kiyohide Fujimoto
View Affiliations

Affiliations: Department of Urology, Nara Medical University, Nara 634‑8522, Japan
Published online on: February 20, 2019 https://doi.org/10.3892/ol.2019.10057
Pages: 4004-4010

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Renal cell carcinoma (RCC) is an immunogenic tumor and pathological specimen generally contain large quantities of tumor‑infiltrating lymphocytes (TILs). Numerous cell types and cytokines could affect the immune escape mechanism of tumor cells. The aim of the present study was to investigate the prognostic impact of TILs and the associated circulating cytokines on localized clear cell RCC following radical nephrectomy. A total of 87 patients who had undergone radical nephrectomy and were pathologically diagnosed with localized clear cell RCC were included. The present study evaluated the profile of TILs with immunohistochemical analysis of tumor specimens using a panel of antibodies [cluster of differentiation (CD)‑4, CD8, CD80, CD86, CD276, and Forkhead box p3 (Foxp3)]. Counts of each TIL were compared with clinicopathological variables. Based on the results of immunohistochemical analyses, putative cytokines, including interleukin (IL)‑6, IL‑10, IL‑17, interferon‑γ, tumor necrosis factor (TNF)‑α, and transforming growth factor (TGF)‑β, were selected, and their levels in preoperative serum were measured by ELISA. The levels were compared with TIL counts in tumor specimens. High counts of the CD276+ and Foxp3+ TILs were identified as independent factors for poor prognosis for metastasis and local recurrence following radical nephrectomy (P=0.033 and 0.006, respectively). A high CD276+ TIL count was associated with preoperative serum levels of TNF‑α and IFN‑γ (P=0.027 and P=0.035, respectively), whereas a high count of Foxp3+ TILs was associated with preoperative serum levels of TGF‑β (P=0.021). High levels of TNF‑α and TGF‑β were associated with recurrence‑free survival (P=0.035 and P=0.031, respectively). Topical intra‑tumoral immunoreaction and systemic immune status may be associated with patients with localized RCC. The topical induction of the CD276+ and Foxp3+ TILs was suggested to be associated with high levels of serum TNF‑α and IFN‑γ. Preoperative serum levels of TNF‑α and TGF‑β could be simple and non‑invasive biomarkers for risk stratification before radical surgery.

View Figures

View References

1	Rini B, Campbell SC and Escudier B: Renal cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
2	Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ and Russo P: Renal cell carcinoma recurrence after nephrectomy for localized disease: Predicting survival from time of recurrence. J Clin Oncol. 24:3101–3106. 2006. View Article : Google Scholar : PubMed/NCBI
3	Miyake M, Kuwada M, Hori S, Morizawa Y, Tatsumi Y, Anai S, Hosokawa Y, Hayashi Y, Tomioka A, Otani T, et al: The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: A Japanese retrospective study. BMC Res Notes. 9:792016. View Article : Google Scholar : PubMed/NCBI
4	Bromwich EJ, McArdie PA, Canna K, McMillan DC, McNicol AM, Brown M and Aitchison M: The relationship between T-lymphocyte infiltration, stage, tumor grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer. 89:1906–1908. 2003. View Article : Google Scholar : PubMed/NCBI
5	Webster WS, Lohse CM, Thompson RH, Dong H, Frigola X, Dicks DL, Sengupta S, Frank I, Leibovich BC, Blute ML, et al: Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer. 107:46–53. 2006. View Article : Google Scholar : PubMed/NCBI
6	Uzzo RG, Rayman P, Kolenko V, Clark PE, Bloom T, Ward AM, Molto L, Tannenbaum C, Worford LJ, Bukowski R, et al: Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res. 5:1219–1229. 1999.PubMed/NCBI
7	Rayman P, Wesa AK, Richmond AL, Das T, Biswas K, Raval G, Storkus WJ, Tannenbaum C, Novick A, Bukowski R and Finke J: Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin Cancer Res. 10:6360S–6366S. 2004. View Article : Google Scholar : PubMed/NCBI
8	Condeelis J and Pollard JW: Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell. 124:263–266. 2016. View Article : Google Scholar
9	Schreiber RD, Old LJ and Smyth MJ: Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science. 311:1565–1570. 2011. View Article : Google Scholar
10	Maxilloux AW and Young MR: Regulatory T-cell trafficking: From thymic development to tumor-induced immune suppression. Crit Rev Immunol. 30:435–447. 2010. View Article : Google Scholar : PubMed/NCBI
11	Liotta F, Gacci M, Frosali F, Querci V, Vittori G, Lapini A, Santarlasci V, Semi S, Cosmi L, Maggi L, et al: Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int. 107:1500–1506. 2011. View Article : Google Scholar : PubMed/NCBI
12	Ye Z, Zheng Z, Li X, Zhu Y, Zhong Z, Peng L and Wu Y: B7-H3 overexpression predicts poor survival of cancer patients: A meta-analysis. Cell Physiol Biochem. 39:1568–1580. 2016. View Article : Google Scholar : PubMed/NCBI
13	Fukuda T, Kamai T, Masuda A, Nukui A, Abe H, Arai K and Yoshida K: Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma. Cancer Med. 5:1810–1820. 2016. View Article : Google Scholar : PubMed/NCBI
14	Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K and Chen L: B7-H3: A costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2:269–274. 2001. View Article : Google Scholar : PubMed/NCBI
15	Anthony LD, Richard ML and Miranda R: Immunity: The immune response in infectious and inflammatory disease. New Sci Press. 3872007.
16	Sobin LH, Gospodarowicz MK and Wittekind CH: International union against cancer. UICC TNM classification of malignant tumors. 7th. Wiley-Liss; pp. 255–257. 2009
17	Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL and Zincke H: An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score. J Urol. 168:2395–2400. 2002. View Article : Google Scholar : PubMed/NCBI
18	Fuhman SA, Lasky LC and Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
19	Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Chen L, Zincke H, Blute ML, Leibovich BC and Kwon ED: Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer. 15:2084–2091. 2005. View Article : Google Scholar
20	Li L, Yang C, Zhao Z, Xu B, Zheng M, Zhang C, Min Z, Guo J and Rong R: Skewed T-helper (Th)1/2- and Th17/T regulatory-cell balances in patients with renal cell carcinoma. Mol Med Rep. 11:947–953. 2015. View Article : Google Scholar : PubMed/NCBI
21	Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH Jr and Patz EF Jr: Tumor infiltrating Foxp3⁺ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 107:2866–2872. 2006. View Article : Google Scholar : PubMed/NCBI
22	Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Hamis AL and Banham AH: Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 24:5373–5380. 2006. View Article : Google Scholar : PubMed/NCBI
23	Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, Zhang Z, Yang H, Zhang H, Zhou C, et al: Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 132:2328–2339. 2007. View Article : Google Scholar : PubMed/NCBI
24	Hiraoka N, Onozato K, Kosuge T and Hirohashi S: Prelavence of Foxp3⁺ regulatory cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 12:5423–5434. 2006. View Article : Google Scholar : PubMed/NCBI
25	Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 10:942–949. 2004. View Article : Google Scholar : PubMed/NCBI
26	Polimeno M, Napolitano M, Costantini S, Portella L, Esposito A, Capone F, Guerriero E, Trotta A, Zanotta S, Pucci L, et al: Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. BJU Int. 112:686–696. 2013. View Article : Google Scholar : PubMed/NCBI
27	Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK and Wang X: B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer. 53:143–151. 2006. View Article : Google Scholar : PubMed/NCBI
28	Sun J, Chen LJ, Zhang GB, Jiang JT, Zhu M, Tan Y, Wang HT, Lu BF and Zhang XG: Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother. 59:1163–1171. 2010. View Article : Google Scholar : PubMed/NCBI
29	Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, et al: Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 14:5150–5157. 2008. View Article : Google Scholar : PubMed/NCBI
30	von Boehmer H: Mechanism of suppression by suppressor T cells. Nat Immunol. 6:338–344. 2005. View Article : Google Scholar : PubMed/NCBI
31	Zhou X, Mao Y, Zhu J, Meng F, Chen Q, Tao L, Li R, Fu F, Liu C, Hu Y, et al: TGF-β1 promotes colorectal cancer immune escape by elevating B7-H3 and B7-H4 via the miR-155/miR-143 axis. Oncotarget. 7:67196–67211. 2016.PubMed/NCBI